[Renal alterations in L-NAME hypertension: influence of losartan and bosentan].
The influence of losartan and the endothelin A and B receptor antagonist, bosentan was assessed on the alterations in renal hemodynamic and function as well as urinary albumin excretion (taken as an index of renal lesions) associated with L-NAME hypertension. L-NAME was given for 4 weeks (20 mg/100 mL in the drinking (fluid) followed by a 2-week period of concomitant treatment with L-NAME and losartan or bosentan (30 and 30 mg/kg, gavage). A group of rats received L-NAME without additional treatment and a group of rats were not given L-NAME and served as normotensive controls. Systolic arterial pressure (SAP) was measured before L-NAME, and before and every 5 days of losartan or bosentan treatment period. Urinary excretion of albumin (UAlb) was determined before and at the end of treatment period. Under anesthesia, glomerular filtration rate (GFR) and renal plasma flow (RPF) were estimated by the clearance method and the filtration fraction was calculated [FF = 100* (GFR/RPF)].